Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Simon Property Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.7 (market cap $5.07B), while Simon Property Group Inc trades at $221 (market cap $71.03B). The key difference: Simon Property Group Inc is far larger — about 14× ACADIA Pharmaceuticals Inc.'s market cap, and Simon Property Group Inc pays a 4.05% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SPG | |
|---|---|---|
Market Cap | $5.07B | $71.03B |
Sector | Health | Real Estate |
52-Week High | $29.41 | $236.70 |
52-Week Low | $20.06 | $169.22 |
Enterprise Value | $4.19B | $99.48B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
SPG trades at $220.55, down 1.06% with a bearish technical signal. The REIT shows strong fundamentals with Q2 2026 FFO beating estimates at $3.29 per share and raised full-year guidance. Valuation metrics appear reasonable with P/E of 15.49 and EV/EBITDA of 11.96, while profitability remains robust with 66.57% net margin and 135.7% ROE. Recent news highlights leasing strength and retailer sales growth driving performance.
The outlook remains positive with analyst consensus at Buy (40.54%) and $226.58 price target offering 2.7% upside. Key risks include interest rate sensitivity from $24.21B debt load and retail sector headwinds. Strong cash flow generation and dividend consistency support the investment case for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
